Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900263 · ClinicalTrials.gov registry record
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
A clinical trial of Multiple Myeloma and Plasma Cell Myeloma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 375
- Enrollment target
- 20
- Study locations
NCT00900263: Completed study of Multiple Myeloma and Plasma Cell Myeloma, sponsored by SWOG Cancer Research Network.
NCT00900263 is a study of Multiple Myeloma and Plasma Cell Myeloma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 375 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900263, a study of Multiple Myeloma and Plasma Cell Myeloma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and bone marrow samples from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma.
Conditions Studied
Interventions
- GENETIC microarray analysis
- OTHER biologic sample preservation procedure
- OTHER laboratory biomarker analysis
- GENETIC cytogenetic analysis
Study Locations (20)
Kansas
- Menorah Medical Center - Overland Park
- Saint Luke's Hospital - South - Overland Park
- Tammy Walker Cancer Center at Salina Regional Health Center - Salina
- Shawnee Mission Medical Center - Shawnee Mission
- Cotton-O'Neil Cancer Center - Topeka
Missouri
- Saint Luke's Cancer Institute at Saint Luke's Hospital - Kansas City
- St. Joseph Medical Center - Kansas City
- North Kansas City Hospital - Kansas City
- Parvin Radiation Oncology - Kansas City
- Heartland Hematology Oncology Associates, Incorporated - Kansas City
Arkansas
- Highlands Oncology Group - Springdale - Bentonville
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
- Clemens Regional Medical Center - Mount Clemens
Alabama
- Providence Cancer Center at Providence Hospital - Mobile
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Illinois
- Veterans Affairs Medical Center - Hines - Hines
Louisiana
- Tulane Cancer Center Office of Clinical Research - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2002-06 |
What the finished NCT00900263 record still lists
NCT00900263 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (31% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which microarray analysis is the first listed.
NCT00900263 names 20 study sites across 10 states, led by Kansas, Missouri, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00900263 about?
NCT00900263 is a clinical study titled "S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma". RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also h...
What is the current status of trial NCT00900263?
This trial is currently completed. The enrollment target is 375 participants. The study started on 2002-06.
What conditions does trial NCT00900263 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition.
What interventions are being tested in trial NCT00900263?
The interventions under investigation include: microarray analysis (GENETIC), biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), cytogenetic analysis (GENETIC).
Who is sponsoring clinical trial NCT00900263?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00900263 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00900263's enrollment target sits among peer trials
375 64th of 438 higher than 375 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia